Absci Corporation has unveiled its summer 2025 corporate presentation highlighting its advancements in AI-driven antibody design and lead optimization. The company showcases its state-of-the-art generative AI models used for de novo antibody design, emphasizing the integration of protein language models and antigen structure predictions. These technologies are employed to create epitope-specific binders, enhancing the pharmacological attributes of antibodies while maintaining developability. The presentation also outlines Absci's ongoing clinical trials and early-stage programs, including ABS-101 and ABS-201, as well as its efforts in data-driven AI model training. You can access the full presentation through the link below.